While the role of these lncRNAs in AD pathology is unknown, SNHG14/UBE3A-ATS has been proposed as a therapeutic target for Angelman syndrome due to its role in silencing the expression of UBE3A [133]. Here, UBE3A is linked to Alzheimer disease.